NeoADAURA plain language summary.pdf (1.01 MB)

NeoADAURA plain language summary: Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy alone for EGFR mutated resectable NSCLC: NeoADAURA.pdf

figure

posted on 2021-07-20, 13:03 authored by Masahiro Tsuboi, Walter Weder, Carles Escriu, Collin Blakely, Jianxing He, Sanja Dacic, Yasushi Yatabe, Lingmin Zeng, Andrew Walding, Jamie E Chaft

Plain Language Summary: Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy alone for EGFR mutated resectable NSCLC: NeoADAURA

Funding

AstraZeneca

History

Usage metrics

Read the peer-reviewed publication

Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy alone for EGFR mutated resectable NSCLC: NeoADAURA

Future Oncology

Keywords

EGFR-TKI-sensitizing mutations EGFR-tyrosine kinase inhibitor neoadjuvant non-small-cell lung cancer osimertinib resectable Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0